Total Payments
$62,101
2024 Payments
$206.80
Companies
14
Transactions
114
Medicare Patients
847
Medicare Billing
$138,420
Payment Breakdown by Category
Consulting$31,845 (51.3%)
Other$18,946 (30.5%)
Travel$5,460 (8.8%)
Food & Beverage$3,820 (6.2%)
Research$2,030 (3.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $31,845 | 7 | 51.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,050 | 9 | 27.5% |
| Travel and Lodging | $5,460 | 27 | 8.8% |
| Food and Beverage | $3,820 | 60 | 6.2% |
| Unspecified | $2,030 | 9 | 3.3% |
| Honoraria | $1,810 | 1 | 2.9% |
| Entertainment | $86.01 | 1 | 0.1% |
Payments by Type
General
$60,071
105 transactions
Research
$2,030
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $39,105 | 66 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $12,833 | 18 | $0 (2018) |
| AbbVie Inc. | $5,778 | 16 | $0 (2021) |
| Eisai Inc. | $1,869 | 2 | $0 (2018) |
| VBI Vaccines (Delaware) Inc. | $1,810 | 1 | $0 (2022) |
| Mallinckrodt Hospital Products Inc. | $188.82 | 2 | $0 (2022) |
| Sirtex Medical Inc | $150.00 | 1 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $118.86 | 2 | $0 (2022) |
| Mirum Pharmaceuticals, Inc. | $86.01 | 1 | $0 (2022) |
| Allergan Inc. | $78.85 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $206.80 | 7 | Gilead Sciences, Inc. ($133.74) |
| 2022 | $2,185 | 6 | VBI Vaccines (Delaware) Inc. ($1,810) |
| 2021 | $264.89 | 3 | AbbVie Inc. ($197.42) |
| 2019 | $5,366 | 18 | Gilead Sciences, Inc. ($5,062) |
| 2018 | $17,532 | 33 | Gilead Sciences, Inc. ($9,653) |
| 2017 | $36,547 | 47 | Gilead Sciences Inc ($24,208) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $32.82 | General |
| Category: LIVER DISEASE | ||||||
| 11/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $89.17 | General |
| 10/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.00 | General |
| 10/21/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: Rare Disease | ||||||
| 09/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.47 | General |
| 06/24/2024 | ORPHALAN INC | CUVRIOR (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: Hepatology | ||||||
| 03/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.10 | General |
| 12/02/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Gastroenterology | ||||||
| 11/05/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $48.87 | General |
| 10/11/2022 | VBI Vaccines (Delaware) Inc. | PreHevbrio (Drug) | Honoraria | Cash or cash equivalent | $1,810.00 | General |
| Category: VACCINE | ||||||
| 05/04/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $78.86 | General |
| Category: Gastroenterology | ||||||
| 04/12/2022 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Entertainment | In-kind items and services | $86.01 | General |
| Category: Alagille syndrome | ||||||
| 03/10/2022 | Mallinckrodt Hospital Products Inc. | — | Food and Beverage | In-kind items and services | $121.35 | General |
| 12/08/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $80.01 | General |
| Category: VIROLOGY | ||||||
| 12/06/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $117.41 | General |
| Category: VIROLOGY | ||||||
| 04/16/2021 | Mallinckrodt Hospital Products Inc. | — | Food and Beverage | In-kind items and services | $67.47 | General |
| 12/10/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $123.33 | General |
| 11/27/2019 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $150.00 | General |
| Category: Interventional Oncology | ||||||
| 11/10/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $107.71 | General |
| 11/08/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $83.40 | General |
| 04/26/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $1,010.00 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis | ||||||
| 04/26/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $459.96 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis | ||||||
| 04/26/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $127.18 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis | ||||||
| 04/26/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $124.99 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis | ||||||
| 04/26/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $98.20 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis | Gilead Sciences, Inc. | $2,030 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 134 | 161 | $60,276 | $22,178 |
| 2022 | 6 | 208 | 265 | $85,984 | $33,495 |
| 2021 | 8 | 257 | 358 | $105,617 | $43,625 |
| 2020 | 7 | 248 | 377 | $110,801 | $39,123 |
Total Patients
847
Total Services
1,161
Medicare Billing
$138,420
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 68 | 91 | $35,416 | $13,519 | 38.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 41 | $11,741 | $4,209 | 35.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $7,306 | $2,246 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,813 | $2,204 | 37.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 89 | 119 | $42,007 | $18,270 | 43.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 51 | $13,501 | $5,400 | 40.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $12,072 | $4,259 | 35.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 16 | $7,762 | $2,601 | 33.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 34 | $8,500 | $2,362 | 27.8% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 21 | 21 | $2,142 | $603.63 | 28.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 62 | 88 | $31,064 | $14,358 | 46.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 66 | 81 | $21,303 | $9,375 | 44.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 29 | 85 | $21,250 | $7,972 | 37.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 25 | 27 | $13,115 | $4,907 | 37.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $8,551 | $3,344 | 39.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 14 | 16 | $4,208 | $1,662 | 39.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 21 | 21 | $3,780 | $1,304 | 34.5% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 23 | 23 | $2,346 | $703.12 | 30.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 88 | 131 | $34,453 | $12,454 | 36.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 61 | 80 | $28,240 | $8,765 | 31.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 86 | $21,500 | $8,026 | 37.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 24 | 26 | $12,636 | $4,699 | 37.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 17 | 17 | $6,817 | $2,539 | 37.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 18 | 21 | $5,523 | $2,109 | 38.2% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2020 | 16 | 16 | $1,632 | $531.24 | 32.6% |
About Dr. Coleman Smith, MD
Dr. Coleman Smith, MD is a Gastroenterology healthcare provider based in Saint Paul, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972563864.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Coleman Smith, MD has received a total of $62,101 in payments from pharmaceutical and medical device companies, with $206.80 received in 2024. These payments were reported across 114 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($31,845).
As a Medicare-enrolled provider, Smith has provided services to 847 Medicare beneficiaries, totaling 1,161 services with total Medicare billing of $138,420. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Saint Paul, MN
- Active Since 03/24/2006
- Last Updated 10/30/2007
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1972563864
Products in Payments
- Epclusa (Drug) $16,255
- Vosevi (Drug) $4,494
- Lenvima (Drug) $1,869
- PreHevbrio (Drug) $1,810
- MAVYRET (Drug) $197.42
- SIR-Spheres Microspheres (Device) $150.00
- Mavyret (Drug) $120.54
- XIFAXAN (Drug) $118.86
- Livmarli (Drug) $86.01
- Vemlidy (Drug) $81.75
- RESMETIROM (Drug) $32.82
- CUVRIOR (Drug) $20.40
- IQIRVO (Drug) $19.84
- Kanuma (Drug) $10.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Saint Paul
Robert Ganz, Md, MD
Gastroenterology — Payments: $158,238
Gastroenterology $158,238
David Weinberg, Md, MD
Gastroenterology — Payments: $63,053
Gastroenterology $63,053
Dr. Robert Mccabe, Md, MD
Gastroenterology — Payments: $21,991
Gastroenterology $21,991
Dr. Anupama Nookala, M.d, M.D
Gastroenterology — Payments: $21,512
Gastroenterology $21,512
Rebecca Li, Md, MD
Gastroenterology — Payments: $20,212
Gastroenterology $20,212
Karin Rettig, Md, MD
Gastroenterology — Payments: $20,127
Gastroenterology $20,127